BioNTech SE
BNTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001776985
In the last 90 days, BioNTech SE insiders filed 0 open-market purchases and 14 sales; 285 institutions reported holding it in 13F filings for Q2 2026, worth $4.36B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $84.2M in total
- 14
- 13F holdersQ2 2026, +11 vs. previous quarter
- 285
- 13F valueReported value at the end of Q2 2026
- $4.36B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in EUR.
- Revenue, FY2025
- EUR 2.87B
- +4.3% year over year
- Net income, FY2025
- EUR -1.14B
- No comparable prior period
- Free cash flow, FY2025
- EUR 280.9M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: EUR 1.14B (39.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.25M
- Shares sold short
- Change
- −26.6K
- −1.2% vs. previous
- Days to cover
- 2.15
- At average daily volume
Superinvestors holding BNTX, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding BioNTech SE on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by BioNTech SE insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2026 (view filing)4:47 PM ET | Oct 8-9 | 1 day | Sahin UgurChief Executive Officer | SSale | −63.2K | $94.07 | −$5.95M | −100.0%0 after | 2 lots10b5-1 |
| Oct 7, 2026 (view filing)5:14 PM ET | Oct 7 | Same day | Sahin UgurChief Executive Officer | SSale | −24.0K | $95.86 | −$2.30M | −27.5%63.2K after | 10b5-1 |
| Oct 6, 2026 (view filing)4:59 PM ET | Oct 5-6 | 1 day | Sahin UgurChief Executive Officer | SSale | −93.0K | $97.14 | −$9.03M | −51.6%87.2K after | 2 lots10b5-1 |
| Oct 2, 2026 (view filing)4:27 PM ET | Oct 1-2 | 1 day | Sahin UgurChief Executive Officer | SSale | −34.0K | $97.09 | −$3.30M | −15.9%180.2K after | 2 lots10b5-1 |
| Sep 30, 2026 (view filing)4:29 PM ET | Sep 29-30 | 1 day | Sahin UgurChief Executive Officer | SSale | −66.0K | $98.19 | −$6.48M | −23.6%214.2K after | 2 lots10b5-1 |
| Sep 28, 2026 (view filing)5:16 PM ET | Sep 25-28 | 3 days | Sahin UgurChief Executive Officer | SSale | −61.0K | $98.57 | −$6.01M | −17.9%280.2K after | 2 lots10b5-1 |
| Sep 24, 2026 (view filing)4:26 PM ET | Sep 23-24 | 1 day | Sahin UgurChief Executive Officer | SSale | −69.0K | $99.17 | −$6.84M | −16.8%341.2K after | 2 lots10b5-1 |
| Sep 22, 2026 (view filing)5:04 PM ET | Sep 21-22 | 1 day | Sahin UgurChief Executive Officer | SSale | −79.0K | $99.50 | −$7.86M | −16.1%410.2K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)4:41 PM ET | Sep 17-18 | 1 day | Sahin UgurChief Executive Officer | SSale | −64.0K | $97.49 | −$6.24M | −11.6%489.2K after | 2 lots10b5-1 |
| Sep 16, 2026 (view filing)4:46 PM ET | Sep 15-16 | 1 day | Sahin UgurChief Executive Officer | SSale | −49.0K | $96.37 | −$4.72M | −8.1%553.2K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 285 holdersThe largest institutional positions in BioNTech SE at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 7,571,805 | $704.6M | 0.03% | +1,862,565+32.6% | Added |
| Primecap Management Co | 3,772,031 | $351.0M | 0.21% | −21,680−0.6% | Reduced |
| Dodge & Cox | 3,677,591 | $342.2M | 0.18% | +8000.0% | Added |
| Flossbach Von Storch AG | 2,226,138 | $207.1M | 0.94% | −1,454,177−39.5% | Reduced |
| T. Rowe Price Investment Management, Inc. | 2,065,456 | $192.2M | 0.13% | −3,790,617−64.7% | Reduced |
| BlackRock, Inc. | 1,854,966 | $172.6M | 0.00% | +196,813+11.9% | Added |
| Temasek Holdings (Private) Ltd | 1,506,027 | $140.1M | 0.38% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 1,319,517 | $122.8M | 0.06% | −332,272−20.1% | Reduced |
| Logos Global Management LP | 1,015,000 | $94.4M | 4.07% | +1,015,000 | New |
| GSK plc | 889,824 | $82.8M | 13.75% | 00.0% | Unchanged |
Holders of 5% or more of BNTX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of BioNTech SE.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Athos KG | 13G/A | 40.20%101.7M shares | – | Feb 16, 20216 filings | May 14, 2026 | SEC |
| Medine GmbH | 13G/A | 17.60%42.2M shares | – | Feb 16, 20215 filings | May 13, 2025 | SEC |
| Sahin Ugur | 13G/A | 15.80%40.1M shares | – | May 15, 20261 filing | May 15, 2026 | SEC |
Politician trades
All politician trades in BNTX2 members of Congress reported 8 trades in BioNTech SE since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Sep 12, 2025 |  Val T. Hoyle House · OR | Sell | $1K-$15K |
| Oct 3, 2024 |  Josh Gottheimer House · NJ | Sell | $1K-$15K |
| Sep 11, 2024 | Josh Gottheimer House · NJ | Sell (partial) | $1K-$15K |
| May 15, 2024 | Josh Gottheimer House · NJ | Buy | $1K-$15K |
| Apr 7, 2024 | Josh Gottheimer House · NJ | Sell | $1K-$15K |
House · OR · Sep 12, 2025
Sell$1K-$15K
House · NJ · Oct 3, 2024
Sell$1K-$15K
House · NJ · Sep 11, 2024
Sell (partial)$1K-$15K
House · NJ · May 15, 2024
Buy$1K-$15K
House · NJ · Apr 7, 2024
Sell$1K-$15K